new glp-1 Pill Foundayo (Orforglipron) Gets FDA Approval for Obesity GLP-1 Pipeline Update: May 2026

Many millions of dollars have been invested by the pharmaceutical industry in developing products, the first of which are now in clinical practice

In short: based on what we know right now, retatrutide side effects may unmask or trigger hair loss indirectly by causing sudden weight loss, calorie restriction, or hormonal and metabolic stress rather than directly poisoning your hair follicles

doi: 10.1016/j.physbeh.2016.03.016 227 WangYChenSXuZChenSYaoWGaoX

Eating at 9pm versus 6pm shows up clearly in your overnight graph

[DOI] [PubMed] [Google Scholar] 103.Neal B., Perkovic V., Matthews D.R

For patients who need a meaningful, evidence-based metabolic interventiona need supported by chronic disease guidelines from the Centers for Disease Control and Prevention (CDC)but have been unwilling or unable to engage with injectables, this pill changes the conversation